Full-Time

Field Service Engineer

Confirmed live in the last 24 hours

Element Biosciences

Element Biosciences

201-500 employees

Next-generation sequencing technology provider

Biotechnology
Healthcare

Compensation Overview

$90k - $110kAnnually

+ Stock Options + Bonus

Mid, Senior

Remote in USA

Remote role based in the Southeast.

Category
Hardware Engineering
Electronic Hardware Engineering
Hardware Validation & Testing

You match the following Element Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Associate or Bachelor Degree with 3+ years of relevant experience in engineering, physics, biology, chemistry or related field (or equivalent combination of education and industry experience)
  • Ability to troubleshoot issues with complex laboratory equipment involving chemistry, software and hardware
  • Strong time management, problem solving, organizational and relationship building skills
  • Excellent verbal and written communications skills, including technical writing abilities
  • Must be flexible in working hours as this position may require customer support during non-regular business hours
Responsibilities
  • Providing onsite installation, qualification, upgrades, repairs and preventative maintenance service on next generation sequencers
  • Identifying root causes and resolving product issues in the field with support when needed
  • Displaying professionalism, understanding, tact and technical knowledge in all customer interactions
  • Implementing and following policies that pertain to the handling of spare parts: ordering, usage, returns, physical count, car stock management, etc.
  • Utilizing service CRM software to accurately document work in a timely manner
Desired Qualifications
  • Experience with NGS sequencing instrument and sequencing run set up preferred
  • Experience servicing scientific instrumentation involving optics, fluid handling and thermal systems
  • Experience with multiple full life cycle product launches preferred
  • Proficient with data collection and analysis tools (eg: in MATLAB, Python, C++ or Java) preferred
  • Experience with fluorescence microscopy helpful
  • Demonstrated account management skills preferred

Element Biosciences specializes in next-generation sequencing (NGS) technology, primarily through its product, the AVITI System. This compact benchtop system provides high-quality DNA sequencing at a low cost, charging only $1 per million reads, which is significantly less than the industry average. The AVITI System is designed to deliver industry-leading accuracy, allowing users, including academic researchers and pharmaceutical companies, to maximize their resources. Element Biosciences differentiates itself from competitors by forming partnerships with other biotech firms, such as QIAGEN, to offer complete NGS workflows, enhancing the value of their product. Additionally, the company runs the 2023 AVITI for All Grant program, which provides free sequencing services to support research across various fields. The goal of Element Biosciences is to make high-quality sequencing accessible and affordable, thereby accelerating research and development in the biotechnology sector.

Company Size

201-500

Company Stage

Series D

Total Funding

$659.5M

Headquarters

San Diego, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Element Biosciences raised $277M in Series D funding, supporting AVITI commercialization.
  • Record growth in AVITI System installations shows strong market acceptance and expansion.
  • Trinity innovation streamlines genomic research, enhancing product offerings and market position.

What critics are saying

  • Competition from Illumina and startups pressures Element to innovate and reduce costs.
  • Reliance on partnerships like QIAGEN and Revvity poses risks if partnerships dissolve.
  • Investment in AVITI24 and Trinity may not yield expected returns if adoption is slow.

What makes Element Biosciences unique

  • Element Biosciences offers the AVITI System, a cost-effective benchtop DNA sequencer.
  • The company's LoopSeq technology enhances sequencing accuracy by avoiding index hopping errors.
  • Partnerships with QIAGEN and Revvity provide comprehensive NGS workflows and neonatal testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

100% company-paid medical, dental, & vision coverage

Flexible spending & health savings accounts

Premier mental health care

401(k) with immediately vested 4% company match

Company-paid Life and AD&D insurance

Stock option grants

Flexible time off

10 paid annual holidays

8-weeks paid parental leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Labiotech
Jan 30th, 2025
Seven Genomics Startups To Look Out For

Newsletter Signup - Under Article / In Page"*" indicates required fields Precision medicine is a kind of treatment strategy that is tailored to individual patients, most of which is dependent on their genetic makeup. Genomics, which deals with the mapping of genomes, is a booming industry that aims to advance precision medicine to address a host of diseases. You may have heard of the big names in the business, like Illumina, Oxford Nanopore Technology, and Thermo Fisher Scientific. But there are a number of genomics startups that have sprouted up in the past decade or so to strengthen their sequencing technologies to aid in disease prevention and treatment. Here are seven genome sequencing startups that are making their mark in the industry.Element BiosciencesFounded in 2017, Element Biosciences shot to fame fairly quickly after the launch of its lab services. Its benchtop sequencing instrument AVITI has a dual flow cell layout and individually addressable lanes and you can perform two parallel runs and operate each side independently. Its alternative model, AVITI LT, is a lower-cost, lower-throughput solution that brings next-generation sequencing (NGS) to more labs.The core components of Element’s sequencing tool include an Avidite base chemistry, which circularizes, copies, and rolls each strand into tightly bound polonies – tiny clusters of identical DNA molecules – without the use of PCR and fluorescent avidites that bind to each polony creating ultrastable complexes. It also employs rolling circle amplification, which is a process that uses a circular DNA template to create long single-stranded DNA molecules to avoid errors such as index hopping – when sequencing reads are incorrectly assigned to the wrong sample in a pool. Its sought-after technology is called LoopSeq, which prepares libraries for long-read sequencing on the short-read Element AVITI System

Stock Titan
Jan 13th, 2025
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

The collaboration combines Revvity's expertise in newborn screening and rare disease detection with Element's AVITI(TM) sequencing system technology.

Forbes
Nov 25th, 2024
Element Biosciences raises $680M funding

Element Biosciences, a U.S. biotech startup, has achieved unicorn status with a valuation over $1 billion and has raised over $680 million. CEO Molly He discussed the company's journey at the Web Summit in Lisbon, highlighting their DNA sequencing device, Aviti, which is used in numerous labs and hospitals. Initial funding included $5 million from Venrock, with subsequent rounds raising $15 million in Series A, $110 million in Series B, and contributions from major investors like Fidelity and RA Capital.

BioSpace
Oct 16th, 2024
Element Biosciences Launches Trinity(TM) - A Revolutionary Targeted Sequencing Innovation to Streamline Genomic Research

Element Biosciences has partnered with Integrated DNA Technologies (IDT) and Twist Bioscience to provide the necessary exome-targeting tools for the Trinity workflow

Daily Investor Hub
Aug 30th, 2024
The $6.3 billion global next-generation sequencing (NGS) market is expected to increase at a substantial pace of 16% by 2026.

In July 2021, Qiagen partnered with Sysmex for the development and marketing of cancer companion diagnostic (CDx) solutions, leveraging Sysmex's Plasma-Safe-SeqS technology for NGS